INCY
★★★★☆ BuymistralIncyte Corporation
Healthcare · sector percentile 100
Session move
$128.12
Vol 0.55× avg
90/100 quant · tgt $127.13
RS60 +32.7% vs SPY · ADV$ 190.8M
session 2026-08-26 · Snapshot — not live tape
Since last scan
2026-08-25 → 2026-08-26
Context only — not a buy/sell signal. Built from scan history and cached news/filings.
Snapshot quote
session 2026-08-26 · scan 2026-08-26 · pushed 08-26 18:57 ET · After hours (stale)
Show quote fundamentalsHide quote fundamentals
- Last (scan/close)
- $129.72
- Previous close
- $129.72
- Pushed last
- $128.12 (stale) · 08-26 18:57 ET · After hours
- Session open
- $129.18
- Last session range
- $127.77 – $129.53
- 52-week range
- $81.09 – $132.60
- Session volume
- 800,046
- Avg volume (20d)
- 1,447,047
- Market cap
- $26.29B
- PE (TTM)
- 16.52
- Forward PE
- 14.51
- Dividend yield
- 0.00%
- 1y target est.
- $127.13
- Next earnings
- 2026-10-27
Snapshot quote — last daily session bars and scan fundamentals. Not live bid/ask or intraday quotes. Pre/after-hours quotes are thinner and may differ from the regular session.
If you put $1,000.00 in
1y ago
$1,510.14
+51%
5y ago
$1,692.92
+69%
Price path only from cached daily closes (adjusted when available). Not dividends cash, fees, or advice.
Market briefing
Curated digest — not a trade signal. Headlines and links as provided by the producer.
- Here’s How Much You Would Have Made Owning Incyte Stock In The Last 20 Years
Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.29% on an annualized basis producing an average annual return of 17.52%. Currently, Incyte has a market capitalization of $25.75 billion.
Benzinga · 2026-08-21
- Canaccord Genuity Initiates Coverage On Incyte with Buy Rating, Announces Price Target of $152
Canaccord Genuity analyst John Newman initiates coverage on Incyte (NASDAQ:INCY) with a Buy rating and announces Price Target of $152.
Benzinga · 2026-08-21
- Tempus AI Just Had Their Entire Strategy Validated By Moderna's Vaccine Advance
Tempus AI remains a strong buy, driven by its unique flywheel business model and recent validation of its technology via the Personalis acquisition. Learn more about TEM stock here.
SeekingAlpha · 2026-08-20
Price Chart
Daily prices from cache
Loading price history…
AI Analysis
- Bull Thesis — Incyte's 92.61 quant score reflects strong revenue/EPS growth (37.7% YoY), 20.3% FCF margin, and 30.7% ROE, underpinned by JAK inhibitor pipeline momentum and expanding oncology portfolio.
- Risks — Form 4 insider selling cluster (2 trades in 14 days) and -15 disclosure score signal potential overhang despite strong fundamentals.
- Target Upside — Mean target of $127.13 implies 2.1% downside vs. $129.72 price, but pipeline catalysts (e.g., ruxolitinib, pemigatinib) could drive upside beyond consensus.
Score History
22 days of scans. Daily batch adds the next weekday automatically while the API is running.
- DatePriceChgScoreRating
- 2026-08-26$129.72+$1.7489.6Buy
- 2026-08-25$127.98+$0.1789.6Buy
- 2026-08-24$127.81+$0.5989.6Buy
- 2026-08-21$127.22−$1.2589.6Buy
- 2026-08-20$128.47+$5.0089.6Buy
- 2026-08-19$123.47−$0.0390.1Strong Buy
- 2026-08-18$123.50+$3.3490.1Strong Buy
- 2026-08-17$120.16−$0.3691.0Strong Buy
- 2026-08-14$120.52+$0.4090.9Strong Buy
- 2026-08-13$120.12−$0.9591.0Strong Buy
- 2026-08-12$121.07−$0.4890.7Strong Buy
- 2026-08-11$121.55+$0.9990.5Strong Buy
- 2026-08-10$120.56$0.0090.8Strong Buy
- 2026-08-09$120.56$0.0093.8Strong Buy
- 2026-08-08$120.56+$2.1893.8Strong Buy
- 2026-08-07$118.38−$1.4290.9Strong Buy
- 2026-08-06$119.80−$0.8091.0Strong Buy
- 2026-08-05$120.60+$2.1790.8Strong Buy
- 2026-08-03$118.43−$1.0990.9Strong Buy
- 2026-08-01$119.52−$0.1390.6Strong Buy
- 2026-07-31$119.65−$3.3490.5Strong Buy
- 2026-07-30$122.99—89.6Buy
Quant Breakdown
Short volume (FINRA)
Off-exchange short sale volume ratio vs recent sessions — not a squeeze forecast.
- Short / total
- 70.7%
- vs 20d (z)
- 0.90
- Short vol
- 194,699
- Status
- ok
Squeeze pressure score
full29/100
- Short leg
- 26
- Call leg
- 41
- Activity
- 0.0
- Call vol share
- 41.9%
- PCR (vol)
- 1.38
- Call OI share
- 48.2%
- ATM IV
- 41.6%
FINRA off-exchange short volume (TRF/ADF consolidated). Not short interest as % of float. Squeeze pressure score (0–100) — free composite of off-exchange short volume and (when available) call-side options activity. Not a probability that a squeeze will occur.
Disclosure score
Rule-based News / Insider / Earnings legs from cached SEC filings — context only, not beat/miss or a buy signal.
Disclosure score
-15
- News
- 0
- Insider
- -15
- Earnings
- 0
Signals below are rule hits from cached filings — Risk / Constructive / Attention. Attention is not a bullish call. Linked chips open the SEC original when available.
Disclosure event score — rule-based view of recent SEC filings and earnings calendar. Not a prediction that price will move, and not earnings beat/miss.
Earnings surprise (quant context)
From Yahoo/public fundamentals cached on the last quant scan — not part of the disclosure event score, and not a buy signal. Figure can lag the latest print.
Last reported surprise +0.4%
Filings & events
Recent SEC disclosures and earnings dates — context only, not a trade signal.
- Next earnings
- 2026-10-27yahoo_calendar
- Last earnings
- —
- SEC ↗42026-08-20
FORM 4
- SEC ↗42026-08-14
FORM 4
- SEC ↗42026-08-07
FORM 4
- SEC ↗42026-08-07
FORM 4
- SEC ↗42026-08-04
FORM 4
- SEC ↗42026-08-04
FORM 4
- SEC ↗10-Q2026-07-28
10-Q
- SEC ↗8-K2026-07-28
8-K
- SEC ↗42026-07-27
FORM 4
- SEC ↗42026-07-27
FORM 4
SEC filings as reported; earnings dates may come from Yahoo calendar. Context only — not investment advice and not a prediction that price will move on a filing or event.